ABSTRACT
Acquired immunodeficiency syndrome (AIDS)-related lymphoma (ARL) is the most lethal complication of human immunodeficiency virus (HIV) infection (1). Although the prevailing pessimism for individuals with AIDS has given way to the successes of potent antiretroviral therapy, the outlook for those with ARL remains distressingly poor. The improved prognosis for HIV-infected individuals has highlighted the need to reduce the incidence, morbidity, and mortality of prognosis-limiting complications such as ARL. Previous chapters have defined developments in standard therapies for ARL. This chapter will discuss future therapies and, in particular, therapies directed by underlying principles of pathogenesis.
